Annovis Bio Inc (ANVS)

Annovis Bio initiated a Phase 3 clinical trial for buntanetap in early Alzheimer's disease and reported increased cash reserves but also an increased net loss per share for Q1 2025 in May 2025. In October 2025, the company announced a $6 million registered direct offering of common stock. Annovis Bio reported its Q3 2025 earnings, missing analysts' consensus estimates, but highlighted the full activation of all 84 sites in its pivotal Phase 3 Alzheimer's study in November 2025. Director Michael Hoffman acquired 39,200 shares of the company's stock, leading to a rise in the stock price in November 2025. The share price was $4.82, representing a decline of 26.52% from November 26, 2024. As of late 2025, the consensus among Wall Street analysts is to "Hold" ANVS shares, with an average price target of $13.50.

Demand for Annovis Bio's products is not subject to typical seasonal fluctuations, as it is a clinical-stage biopharmaceutical company focused on chronic neurodegenerative diseases. Demand is primarily driven by the prevalence of diseases like Alzheimer's and Parkinson's, the progression of its drug candidates through clinical trials, regulatory approvals, and the eventual efficacy and market adoption of its therapies. The company currently generates no revenue from product sales, with its valuation tied to clinical trial outcomes and market sentiment.

Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases like Alzheimer's and Parkinson's. The company's core business model centers around its pipeline of drug candidates designed to inhibit the production of neurotoxic proteins. Its lead drug candidate, Buntanetap, is in Phase 3 clinical trials for Alzheimer's and Parkinson's, and Phase 2 trials for Lewy Body Dementia. ANVS405, an intravenous formulation of Buntanetap, is in Phase 2 and 3 trials for acute neurodegenerative conditions. ANVS301 has completed Phase 1 trials and is being developed to enhance cognitive function in later stages of Alzheimer's and dementia.

Annovis Bio, Inc. is headquartered in Malvern, Pennsylvania, United States. The company primarily develops drugs to treat neurodegeneration in the United States, with plans to expand internationally through partnerships and collaborations.

Annovis Bio is recognized as a neuroscience biotech company focused on developing treatments for Alzheimer's and Parkinson's diseases, with its reputation tied to the progress of its clinical trials for Buntanetap. The FDA granted clearance for Annovis Bio to proceed with a pivotal Phase 3 study for early Alzheimer's disease, based on promising Phase 2/3 clinical data. The launch of the pivotal Phase 3 AD study in early 2025 and the full activation of all trial sites in Q3 2025 demonstrate continued progress. Annovis Bio received a notice from the New York Stock Exchange regarding non-compliance with continued listing standards, as its average global market capitalization fell below $50 million. The significant decline in stock value over the past year can also affect brand perception among investors.

Individual investors hold the largest share at 59%, while insiders own 31% of Annovis Bio, Inc. Michael M. Hoffman, Chairman of the Board, is a significant individual shareholder. Maria Maccecchini, Founder, President, CEO, and Executive Board Member, is the second-largest individual shareholder. There are 51 institutional owners holding a total of 2,170,677 shares, including Vanguard Group Inc., Susquehanna International Group, Llp, and BlackRock, Inc.